Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Powell

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2024
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical TrialAnn H Klopp, Danielle Enserro, Matthew Powell, et al.
Ejhaem|May 1, 2025
Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of IrelandEdmund C R Watson, Faouzi Djebbari, Fotios Panitsas, et al.
The Journal of Clinical Investigation|May 20, 2025
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancerAngela Schab, Amanda Compadre, Rebecca Drexler, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancerAngela Schab, Amanda Compadre, Rikki Drexler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005Jung-Min Lee, Mark F Brady, Austin Miller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 19, 2025
Multi-center, international endometrial cancer consortium highlightsLuigi De Vitis, Anna Giudici, Vincenzo Tarantino, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanismsElena Lomonosova, Megan Loeb, Kevin Rodriguez, et al.
JAMA|September 3, 2020
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical TrialDerek C Angus, Lennie Derde, Farah Al-Beidh, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2024
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical TrialAnn H Klopp, Danielle Enserro, Matthew Powell, et al.
Ejhaem|May 1, 2025
Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of IrelandEdmund C R Watson, Faouzi Djebbari, Fotios Panitsas, et al.
The Journal of Clinical Investigation|May 20, 2025
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancerAngela Schab, Amanda Compadre, Rebecca Drexler, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancerAngela Schab, Amanda Compadre, Rikki Drexler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005Jung-Min Lee, Mark F Brady, Austin Miller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 19, 2025
Multi-center, international endometrial cancer consortium highlightsLuigi De Vitis, Anna Giudici, Vincenzo Tarantino, et al.
Biorxiv : the Preprint Server for Biology|August 13, 2025
Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanismsElena Lomonosova, Megan Loeb, Kevin Rodriguez, et al.
JAMA|September 3, 2020
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical TrialDerek C Angus, Lennie Derde, Farah Al-Beidh, et al.
Pageof 6